alpha1-antitrypsin deficiency

α1-an·ti·tryp·sin de·fi·cien·cy

absence of a serum proteinase inhibitor that may cause relapsing nodular nonsuppurative panniculitis.
References in periodicals archive ?
Awards fund early career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency.
Awards fund early-career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency
Evaluation of an integrative diagnostic algorithm for the identification of people at risk for alpha1-antitrypsin deficiency.
to support research into alpha1-antitrypsin deficiency, a genetic condition in which low levels of the essential blood protein alpha1-proteinase inhibitor, can cause emphysema.
Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency.
Alpha1-Antitrypsin Deficiency affects approximately 100,000 Europeans and a similar number in the United States, according to the Alpha-1 Foundation, a not-for-profit organization dedicated to increasing the awareness and early diagnosis of this life-threatening genetic disorder.
emphysema cases are people who have inherited from both parents the gene for alpha1-antitrypsin deficiency.
Kamada's drug may be the world's first drug designed to treat patients suffering from genetic Alpha1-Antitrypsin Deficiency through inhalation.
5, 2013 /PRNewswire/ -- Grifols, a global healthcare company based in Barcelona, Spain, is commemorating the 25th anniversary year of PROLASTIN (alpha1-proteinase inhibitor[human]) and the 50th anniversary of the discovery of alpha1-antitrypsin deficiency (Alpha1) with a series of events and programs around the world aimed at raising awareness and advancing research into the treatment of alpha1.
Inherited chronic obstructive pulmonary disease: new selective-sequencing workup for alpha1-antitrypsin deficiency identifies 2 previously unidentified null alleles.
The agreement with Kamada underscores Baxter's commitment to expanding the diagnosis of alpha1-antitrypsin deficiency by bringing new and innovative therapeutic options to Alpha-1 patients and their treating physicians," said Larry Guiheen, president of Global BioPharmaceuticals, Baxter BioScience.
Awards fund early career investigators' research to advance understanding and potential treatments of alpha1-antitrypsin deficiency